Kennedy Capital Management, Inc. Aldeyra Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $3.99 Billion
- Q1 2025
A detailed history of Kennedy Capital Management, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 1,233,414 shares of ALDX stock, worth $5.24 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
1,233,414
Previous 1,468,519
16.01%
Holding current value
$5.24 Million
Previous $7.33 Million
3.21%
% of portfolio
0.18%
Previous 0.17%
Shares
6 transactions
Others Institutions Holding ALDX
# of Institutions
142Shares Held
38.6MCall Options Held
620KPut Options Held
435K-
Perceptive Advisors LLC New York, NY9.28MShares$39.4 Million2.23% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$23.3 Million21.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$15.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$15.4 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.75MShares$7.44 Million2.26% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $248M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...